It all comes down to one simple priority: ensuring that patients with rare diseases have timely access to our life-changing therapies, while delivering sustainable business growth in alignment with Recordati’ s mission. We’re talking about very small, often overlooked patient groups, so every single person matters.
Tell us about your background. I am British with a Ph.D in chemistry from Oxford University and an MBA from Alliance Manchester Business School. I started out marketing highly scientific products in diagnostics, biotech and pharma, made the move to Business Development around 2005 and haven’t looked back since, doing exciting deals in pharma, CDMO and biotech. My dealmaking experience covers the full range from technology licensing, discovery deals, product in and out-licensing, M&A, divestments and spin-offs.
Tell us more about ten23 health, why did you decide to found the company and the origin of the name.
ten23 health is a pharmaceutical service provider, supporting our pharma and biotech customers in developing safe, usable, convenient, stable and efficient medicines for their patients. Human-centricity and sustainability are key components of how we act and operate.
